Skip to Main content Skip to Navigation
Journal articles

In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus (HBV) mutants.

Abstract : The susceptibility of drug-resistant hepatitis B virus (HBV) mutants to lamivudine, adefovir, tenofovir, entecavir and 2,4-diamino-6-[2-(phosphonomethoxyethoxy]pyrimidine (PMEO-DAPym), a novel acyclic pyrimidine analogue, was assessed in vitro. Most drug-resistant mutants, including multidrug resistant strains, remained sensitive to tenofovir and PMEO-DAPym. Therefore, the latter molecule deserves further evaluation for the treatment of HBV infection.
Complete list of metadatas

Cited literature [23 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-00139473
Contributor : Fabien Zoulim <>
Submitted on : Monday, April 2, 2007 - 3:09:35 PM
Last modification on : Thursday, November 19, 2020 - 11:06:10 AM
Long-term archiving on: : Wednesday, April 7, 2010 - 1:48:48 AM

Identifiers

Collections

Citation

Marie-Noëlle Brunelle, Julie Lucifora, Johan Neyts, Stéphanie Villet, Antony Holy, et al.. In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus (HBV) mutants.. Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2007, 51 (6), pp.2240-3. ⟨10.1128/AAC.01440-06⟩. ⟨inserm-00139473⟩

Share

Metrics

Record views

436

Files downloads

227